Is it possible NET-redifferentiation after chemotherapy? 68Ga DOTA-peptide imaging as a game-changer in therapy management ¿Es posible la rediferenciación de NET tras la quimioterapia? Captación de imágenes de DOTA-péptidos marcados con 68Ga como cambio de estrategia en el tratamiento terapéutico
Revista Espanola de Medicina Nuclear e Imagen Molecular, cilt.39, sa.1, ss.31-34, 2020 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 39 Sayı: 1
- Basım Tarihi: 2020
- Doi Numarası: 10.1016/j.remn.2018.10.002
- Dergi Adı: Revista Espanola de Medicina Nuclear e Imagen Molecular
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, DIALNET
- Sayfa Sayıları: ss.31-34
- Anahtar Kelimeler: Neuroendocrine tumors, Peptide receptor radionuclide therapy, Ga-68 PET/CT, Redifferentiation
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
A 64-year-old man with pancreatic grade III neuroendocrine carcinoma underwent 68Ga DOTANOC PET/CT scan for staging. The pancreatic lesion, multiple peripancreatic lymph nodes and multiple gross metastases in both hepatic lobes were revealed with intense uptake. After 3 cycles of chemotherapy containing cisplatin and etoposide the primary and metastatic lesions were decreased in size, however showing higher uptake on follow-up 68Ga DOTANOC PET/CT scan. Another biopsy from liver demonstrated a significant decrease in Ki-67 proliferation index from 35 to 1%. The patient received 2 cycles of peptide receptor-targeted radionuclide therapy with 177Lu DOTANOC.